Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

Pimasertib Versus Dacarbazine in Patients With Unresectable <i>NRAS</i>-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover

This study investigated the efficacy and safety of pimasertib (<i>MEK</i>1/<i>MEK</i>2 inhibitor) versus dacarbazine (DTIC) in patients with untreated <i>NRAS</i>-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM...

Full description

Bibliographic Details
Main Authors: Celeste Lebbé, Caroline Dutriaux, Thierry Lesimple, Willem Kruit, Joseph Kerger, Luc Thomas, Bernard Guillot, Filippo de Braud, Claus Garbe, Jean-Jacques Grob, Carmen Loquai, Virginia Ferraresi, Caroline Robert, Paul Vasey, Robert Conry, Richard Isaacs, Enrique Espinosa, Armin Schueler, Giorgio Massimini, Brigitte Dréno
Format: Article
Language:English
Published: MDPI AG 2020-06-01
Series:Cancers
Subjects:
malignant melanoma
dacarbazine
pimasertib
N-(2,3-dihydroxypropyl)-1-((2-fluoro-4-iodophenyl)amino)isonicotinamide
progression-free survival
quality of life
Online Access:https://www.mdpi.com/2072-6694/12/7/1727

Internet

https://www.mdpi.com/2072-6694/12/7/1727

Similar Items